Identification of Genetic Variants in Progressive Supranuclear Palsy in Southeast Asia

Adeline Su Lyn Ng,Ai Huey Tan,Yi Jayne Tan,Jia Lun Lim,Michelle Mulan Lian,Alfand Marl Dy Closas,Azlina Ahmad‐Annuar,Shanthi Viswanathan,Yuen Kang Chia,Jia Nee Foo,Weng Khong Lim,Eng‐King Tan,Shen‐Yang Lim

DOI: https://doi.org/10.1002/mds.29932

IF: 9.698

2024-08-19

Movement Disorders

Abstract:In a study of 182 progressive supranuclear palsy (PSP) patients from Asian cohorts, 17 pathogenic/likely pathogenic variants were identified in 16 PSP patients (9%), 8 of which were novel. The genetic findings in the Asian PSP cohorts differ from those in Western populations, and suggest an overlap in genetic architecture between PSP and other neurodegenerative diseases. Background Progressive supranuclear palsy (PSP) is largely a sporadic disease with few reported familial cases. Genome‐wide association studies (GWAS) in sporadic PSP in Caucasian populations have identified MAPT as the most commonly associated genetic risk locus with the strongest effect size. At present there are limited data on genetic factors associated with PSP in Asian populations. Objectives Our goal was to investigate the genetic factors associated with PSP in Southeast Asian PSP patients. Methods Next‐generation sequencing (whole‐exome, whole‐genome and targeted sequencing) was performed in two Asian cohorts, comprising 177 PSP patients. Results We identified 17 pathogenic or likely pathogenic variants in 16 PSP patients (9%), eight of which were novel. The most common relevant genetic variants identified were in MAPT, GBA1, OPTN, SYNJ1, and SQSTM1. Other variants detected were in TBK1, PRNP, and ABCA7—genes that have been implicated in other neurodegenerative diseases. Eighteen patients had a positive family history, of whom two carried pathogenic MAPT variants, and one carried a likely pathogenic GBA1 variant. None of the patients had expanded repeats in C9orf72. Furthermore, we found 16 different variants of uncertain significance in 21 PSP patients in PSEN2, ABCA7, SMPD1, MAPT, ATP13A2, OPTN, SQSTM1, CYLD, and BSN. Conclusions The genetic findings in our PSP cohorts appear to be somewhat distinct from those in Western populations, and also suggest an overlap of the genetic architecture between PSP and other neurodegenerative diseases. Further functional studies and validation in independent Asian cohorts will be useful for improving our understanding of PSP genetics and guiding genetic screening strategies in these populations. © 2024 International Parkinson and Movement Disorder Society.

clinical neurology